A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...
The role of PCSK9 inhibitors as treatment for dyslipidemia now that statin therapies are available. Deepak L. Bhatt, MD, MPH: Speaking of PCSK9 inhibitors, let’s turn back to Dr Budoff. I was going to ...
Richa Munjal considers the current landscape for PCSK9 inhibitors and whether there is a brighter future on the horizon for this class of drugs. The promise of a new era of cholesterol management, ...
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...
A draft report on the value-based price benchmark for the newly approved PCSK9 inhibitors for lowering bad cholesterol found that Repatha and Praluent should cost approximately 85% less than their ...
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing ...
Although some of the barriers that have kept cholesterol-lowering PCSK9 inhibitors out of reach for many patients in the United States have eased a bit in recent years, a new analysis suggests that ...
BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...
New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | ...
The quest to inhibit the cholesterol-related enzyme PCSK9 has produced two high-profile drugs and a massive patent battle between their makers. Now a group of scientists in Europe, along with the ...
Please provide your email address to receive an email when new articles are posted on . The role of PCSK9 inhibitors in the field of CV medicine continues to evolve, as data accumulate showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results